The latest techniques and management strategies in cardiovascular and thoracic critical care and enhanced recovery after surgery for the entire care team.
A world-class, international event that will explore the latest developments and best practices in coronary artery disease, congenital heart disease, thoracic aortic disease, atrial fibrillation, and the surgical management of heart failure
The premier annual event in cardiothoracic surgery, unveiling never-before-seen science, techniques, and technology, and creating a forum to build lasting connections with colleagues.
Diversity in the physician workforce is a key component of delivering the best care to our increasingly heterogeneous patient population. The experience of Asians in cardiothoracic surgery is not well known. With a paucity of published evidence, the webinar panel will introduce the topic through the lived experience of Asians in the specialty. The discussion will explore:
Aortic regurgitation is an undertreated condition, often because patients are not referred in a timely fashion for intervention. During this STS webinar, attendees will hear from an expert panel on the evidence base for timing of intervention as well as evolving treatment options. Conventional surgical aortic valve repair can be considered alongside the Ross procedure and transcatheter interventions with dedicated devices. Webinar participants will be better informed on how to treat this patient population.
The management of stage IIIA non-small cell lung cancer (NSCLC) is evolving in the era of immune checkpoint inhibitor therapy. In the past, there has been a great deal of controversy regarding the optimal management of patients with N2 nodal metastasis at the time of diagnosis of NSCLC. There are some new questions to address when considering the results of the Checkmate 816 and the NADIM II clinical trials which demonstrated improved disease-free survival and overall survival with neoadjuvant combined chemotherapy and Nivolumab.
Recent approvals by the U.S. Food and Drug Administration (FDA) have made available two new technologies for treating aortic disease. The GORE® TAG® Thoracic Branch Endoprosthesis (TBE) is single-branch aortic stent graft that provides an off-the-shelf solution for patients that need zone II aortic coverage and obviates the need for prior left subclavian revascularization. The Thoraflex Hybrid Frozen Elephant Trunk (FET) device is a pre-mated surgical graft and an aortic stent graft to facilitate single-stage treatment of arch and proximal descending aortic pathologies.
